IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells

Cancer Immunology, Immunotherapy

Volumn 65, Issue 2, 2016, Pages 193-204

  Ohno, Yosuke ^a,b   Kitamura, Hidemitsu ^a   Takahashi, Norihiko ^b   Ohtake, Junya ^a   Kaneumi, Shun ^a   Sumida, Kentaro ^a   Homma, Shigenori ^b   Kawamura, Hideki ^b   Minagawa, Nozomi ^b   Shibasaki, Susumu ^b   Taketomi, Akinobu ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antigen presentation; Dendritic cells; Helper T cells; HLA class II; IL 12

Indexed keywords

ARGINASE; CD11 ANTIGEN; CD86 ANTIGEN; CYCLOOXYGENASE 2; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 6; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CELL MEMBRANE; COLORECTAL TUMOR; DENDRITIC CELL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGEN PRESENTATION; ANTIGENS, CD11; ANTIGENS, CD86; ANTIGENS, NEOPLASM; ARGINASE; CD4-POSITIVE T-LYMPHOCYTES; CELL MEMBRANE; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS;

EID: 84955688942     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1791-4     Document Type: Article

References (44)

1. Savage PA, Malchow S, Leventhal DS (2013) Basic principles of tumor-associated regulatory T cell biology. Trends Immunol 34:33–40. doi:10.1016/j.it.2012.08.005
2. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253–268. doi:10.1038/nri3175
3. Motz GT, Coukos G (2013) Deciphering and reversing tumor immune suppression. Immunity 39:61–73. doi:10.1016/j.immuni.2013.07.005
4. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. doi:10.1056/NEJMoa1003466
5. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133. doi:10.1056/NEJMoa1302369
6. Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465. doi:10.1056/NEJMoa1200694
7. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265–277. doi:10.1038/nrc3258
8. Palucka K, Banchereau J (2013) Dendritic-cell-based therapeutic cancer vaccines. Immunity 39:38–48. doi:10.1016/j.immuni.2013.07.004
9. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449:419–426
10. Steinman RM, Mellman I (2004) Immunotherapy: bewitched, bothered, and bewildered no more. Science 305:197–200. doi:10.1126/science.1099688
11. Hirano T, Ishihara K, Hibi M (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19:2548–2556
12. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73–76. doi:10.1038/324073a0
13. Kitamura H, Kamon H, Sawa SI, Park SJ, Katunuma N, Ishihara K, Murakami M, Hirano T (2005) IL-6-STAT3 controls intracellular MHC class II αβ dimer level through cathepsin S activity in dendritic cells. Immunity 23:491–502. doi:10.1016/j.immuni.2005.09.010
14. Park SJ, Nakagawa T, Kitamura H, Atsumi T, Kamon H, Sawa SI, Kamimura D, Ueda N, Iwakura Y, Ishihara K, Murakami M, Hirano T (2004) IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 173:3844–3854. doi:10.4049/jimmunol.173.6.3844
15. Sumida K, Wakita D, Narita Y, Masuko K, Terada S, Watanabe K, Satoh T, Kitamura H, Nishimura T (2012) Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol 42:2060–2072. doi:10.1002/eji.201142335
16. Narita Y, Kitamura H, Wakita D, Sumida K, Masuko K, Terada S, Nakano K, Nishimura T (2013) The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice. J Immunol 190:812–820. doi:10.4049/jimmunol.1103797
17. Ohtake J, Ohkuri T, Togashi Y, Kitamura H, Okuno K, Nishimura T (2014) Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. Immunol Lett 161:20–30. doi:10.1016/j.imlet.2014.04.010
18. Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato S, Kimura K, Kitada M, Tateno M, Celis E, Kobayashi H (2011) Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. J Transl Med 9:191. doi:10.1186/1479-5876-9-191
19. Knüpfer H, Preiss R (2010) Serum interleukin-6 levels in colorectal cancer patients–a summary of published results. Int J Colorectal Dis 25:135–140. doi:10.1007/s00384-009-0818-8
20. Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Furuse J, Inagaki M, Higashi S, Kato H, Terao K, Ochiai A (2013) Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 108:2063–2069. doi:10.1038/bjc.2013.174
21. Gupta N, Goswami B, Mittal P (2012) Effect of standard anthracycline based neoadjuvant chemotherapy on circulating levels of serum IL-6 in patients of locally advanced carcinoma breast—a prospective study. Int J Surg 10:638–640. doi:10.1016/j.ijsu.2012.11.007
22. Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H (2012) Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 3:463–469. doi:10.3892/etm.2011.424
23. Hoentjen F (2005) STAT3 regulates NF-B recruitment to the IL-12p40 promoter in dendritic cells. Blood 105:689–696. doi:10.1182/blood-2004-04-1309
24. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H (2009) Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15:114–123. doi:10.1016/j.ccr.2008
25. Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, Montagna C, Feldman GM, Nishikomori R, O’Shea JJ (2002) STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci U S A 99:12281–12286. doi:10.1073/pnas.182618999
26. Hsich CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophage. Science 260:547–549. doi:10.1126/science.8097338
27. Kaliński P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML (1997) IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 159:28–35
28. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohta A (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190:617–627. doi:10.1084/jem.190.5.617
29. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698–2703. doi:10.1056/NEJMoa0800251
30. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M (2006) IL-23 promotes tumour incidence and growth. Nature 442:461–465. doi:10.1038/nature04808
31. Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Togashi Y, Kitamura H, Todo S, Nishimura T (2012) First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 103:150–153. doi:10.1111/j.1349-7006.2011.02106.x
32. Harizi H, Juzan M, Grosset C, Rashedi M, Gualde N (2001) Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol 209:19–28. doi:10.1006/cimm.2001.1785
33. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P (2011) Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118:5498–5505. doi:10.1182/blood-2011-07-365825
34. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P, Torri V, Repici A, Santoro A, Mantovani A, Roncalli M, Malesci A (2009) CD3+ cells at the invasive margin of deeply invading (pT3–T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 10:877–884. doi:10.1016/S1470-2045(09)70186-X
35. Huh JW, Lee JH, Kim HR (2012) Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. Arch Surg 147:366–372. doi:10.1001/archsurg.2012.35
36. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782–795. doi:10.1016/j.immuni.2013.10.003
37. Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, Bindea G, Ferariu D, Danciu M, Bruneval P, Scripcariu V, Chevallier JM, Zinzindohoué F, Berger A, Galon J, Pagès F (2014) Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 20(7):1891–1899. doi:10.1158/1078-0432.CCR-13-2830
38. Maby P, Tougeron D, Hamieh M, Mlecnik B, Kora H, Bindea G, Angell HK, Fredriksen T, Elie N, Fauquembergue E, Drouet A, Leprince J, Benichou J, Mauillon J, Le Pessot F, Sesboué R, Frebourg T, Galon J, Latouche JB (2015) Correlation between density of CD8+ T cell infiltrates in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res 75(17):3446–3455. doi:10.1158/0008-5472.CAN-14-3051
39. Simpson JAD, Al-Attar A, Watson NFS, Scholefield JH, Ilyas M, Durrant LG (2010) Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 59:926–933. doi:10.1136/gut.2009.194472
40. Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, Xu H, Meeker AK, Fan J, Cheadle C, Berger AE, Pardoll DM, Topalian SL (2015) Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res 21(17):3969–3976. doi:10.1158/1078-0432.CCR-15-0244
41. Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R (2014) A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 20:2192–2204. doi:10.1158/1078-0432.CCR-13-2200
42. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK (2013) A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 161:357–366. doi:10.1111/bjh.12266
43. Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR (2012) Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 48:85–93. doi:10.1016/j.ejca.2011.10.014
44. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17:6083–6096. doi:10.1158/1078-0432.CCR-11-0945